News | March 11, 2009

First Patient is Treated With GORE Flow Reversal System

March 10, 2009 - W. L. Gore & Associates today said the first clinical use of the GORE Flow Reversal System for neuroprotection during carotid artery stenting (CAS) was performed by Daniel McCormick, M.D. and Sheldon Goldberg, M.D., interventional cardiologists at Hahnemann University Hospital, Philadelphia.

Gore obtained 510(k) clearance from the FDA for the system in February. The GORE Flow Reversal System is a new technology, which minimizes the risk of emboli reaching the brain during critical stages of CAS, thereby expanding treatment options for broad patient populations with carotid artery disease.

“We are pleased to be the first site to perform a procedure using the commercially available GORE Flow Reversal System,” said Dr. McCormick. “I believe this new development in carotid artery stenting is a promising advancement in the treatment of carotid disease.”

The first patient was recently symptomatic with an extreme aortic arch and a string sign lesion in the internal carotid artery. The lesion was successfully treated under neuroprotection using the GORE Flow Reversal System. The patient was discharged from the hospital and is doing well.

“I was impressed that the GORE Flow Reversal System negotiated the Type III aortic arch with ease,” stated Dr. McCormick. “Treating this extremely tight stenosis and challenging arch anatomy under flow reversal provided me with a level of performance and confidence that would have been improbable with other embolic protection devices.”

One of the major challenges associated with CAS is the risk of periprocedural embolic events that could cause a stroke. The GORE Flow Reversal System establishes neuroprotection by reversing blood flow at the treatment site prior to crossing the lesion. The company said flow reversal is achieved by selectively occluding common carotid and external carotid artery blood flow. By establishing an arterio-venous shunt, blood from collateral vessels via the Circle of Willis is redirected to the lower pressure venous return. Macro and micro emboli are continuously directed away from the brain during flow reversal.

Prior to the procedure, Dr. McCormick attended a GORE Medical Mastery Series Flow Reversal Course to gain familiarity with the system. This course allows clinicians to perform simulated carotid artery procedures using the product and educates physicians on how flow reversal makes the promise of carotid artery stenting possible.

Gore is conducting other studies in the area of stroke intervention including the Gore REDUCE Clinical Study evaluating the GORE HELEX Septal Occluder for patent foramen ovale closure and stroke prevention, and the Gore EMBOLDEN Clinical Study evaluating the GORE Embolic Filter in CAS.
*REDUCE: GORE HELEX Septal Occluder and Antiplatelet Medical Management for Reduction of Recurrent Stroke or Imaging-Confirmed TIA in Patients with Patent Foramen Ovale (PFO)

For more information: www.goremedical.com

Related Content

The Boston Scientific FilterWire EZ embolic protec filter system.

The Boston Scientific FilterWire EZ embolic protection system.

News | Embolic Protection Devices| October 31, 2017
October 31, 2017 — The VAMPIRE 3 study evaluated if the selective use of distal filter protection might decrease the
Claret Medical Closes $14.5 Million in Series C Financing for Sentinel Cerebral Protection System
News | Embolic Protection Devices| October 23, 2017
October 23, 2017 — Claret Medical announced that it has closed on a Series C financing of $14.5 million led by Lights
Sentinel Cerebral Protection System Significantly Reduces Stroke and Mortality in TAVR
News | Embolic Protection Devices| September 18, 2017
September 18, 2017 – Claret Medical announced publication of a new study in the...
Protembis Announces Successful First-in-Human Use of  ProtEmbo Cerebral Protection System in European Trial
News | Embolic Protection Devices| September 07, 2017
Protembis GmbH announced the first clinical applications of its ProtEmbo Cerebral Protection System to complement a...
PinnacleHealth First in Pennsylvania to Implant Sentinel Cerebral Protection System
News | Embolic Protection Devices| August 23, 2017
PinnacleHealth is the first hospital in Pennsylvania and one of the first 10 in the country to introduce new technology...
PinnacleHealth Initiates Clinical Study of TriGuard Embolic Protection Device
News | Embolic Protection Devices| April 11, 2017
Through a new clinical trial, patients at Harrisburg, Pa.-based PinnacleHealth have access to an investigational device...
Cardiogard embolic protection system for surgical valve reaplacement

The CardioGard embolic protection system for surgical aortic valve replacement.

Feature | Embolic Protection Devices| March 22, 2017
March 22, 2017 — Two U.S.
Keystone Heart, TriGuard Embolic Protection Device, real-world results, PCR London Valves Conference 2016
News | Embolic Protection Devices| September 29, 2016
Keystone Heart Ltd. recently announced the safety and efficacy of the TriGuard Cerebral Embolic Protection device...
Claret Medical, Sentinal CPS, cerebral protection system, FDA marketing application, TAVR, embolic protection
News | Embolic Protection Devices| September 20, 2016
Claret Medical announced its filing of a marketing application with the U.S. Food and Drug Administration (FDA) for...
InspireMD, CGuard, PARADIGM study, EuroPCR 2015, Musialek

Image courtesy of InspireMD

News | Embolic Protection Devices| June 23, 2015
InspireMD Inc. announced that its CGuard embolic prevention system reported positive results in the PARADIGM study at...
Overlay Init